Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus (HIV)-positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti-thymocyte globulin (ATG) administration. We observed improvement in renal function without HIV disease progression or opportunistic infections. Donor-specific antibodies appeared shortly after conversion but cleared without intervention. This case highlights belatacept as a means to improve renal function and avoid significant drug interactions even following ATG induction.
|Original language||English (US)|
|Journal||Transplant Infectious Disease|
|State||Published - Oct 1 2017|
- human immunodeficiency virus
- kidney transplantation
ASJC Scopus subject areas
- Infectious Diseases